Geron Announces Two Oral Presentations on Imetelstat at Upcoming American Society of Hematology Annual Meeting
November 01 2018 - 6:20AM
Clinical Data from Part 1 of IMerge in
Myelodysplastic Syndromes and IMbark Primary Analysis in
Myelofibrosis to be Presented
Geron Corporation (Nasdaq: GERN) today announced that
clinical data related to imetelstat, the Company’s first-in-class
telomerase inhibitor, will be the subject of two oral presentations
at the 60th American Society of Hematology (ASH) Annual Meeting and
Exposition to be held in San Diego, California from December 1-4,
2018. The abstracts, summarizing clinical data from Part 1 of
IMerge in myelodysplastic syndromes and the IMbark primary analysis
in myelofibrosis, were published today on the ASH website at
www.hematology.org.
“We are pleased the abstracts for Part 1 of IMerge and IMbark
were accepted for presentation at ASH,” said John A. Scarlett,
M.D., Geron’s President and Chief Executive Officer. “We are
looking forward to the oral presentations as they underscore
imetelstat’s potential to address the unmet medical need in lower
risk MDS and relapsed/refractory myelofibrosis.”
Oral Presentations
Title: Imetelstat Treatment Leads to Durable Transfusion
Independence (TI) in RBC Transfusion-Dependent (TD), Non-Del(5q)
Lower Risk MDS Relapsed/Refractory to Erythropoiesis-Stimulating
Agent (ESA) Who Are Lenalidomide and HMA Naïve (Abstract
#463)
Session Name: 637. Myelodysplastic Syndromes—Clinical Studies:
Novel Therapeutics II Session Date: Sunday, December 2, 2018
Session Time: 4:30 p.m. PT - 6:00 p.m. PT Presentation Time:
4:30 p.m. PT The oral presentation is expected to provide more
mature efficacy and safety data from the combined initial and
expansion cohorts in Part 1 of IMerge, a Phase 2 clinical trial of
imetelstat in transfusion dependent, lower risk myelodysplastic
syndromes (MDS) patients who are relapsed or refractory to an
erythropoiesis stimulating agent (ESA), do not have a del(5q)
chromosomal abnormality and are hypomethylating agent (HMA) and
lenalidomide treatment naïve.
Title: Imetelstat Is Effective Treatment for Patients
with Intermediate-2 or High-Risk Myelofibrosis Who Have Relapsed on
or Are Refractory to Janus Kinase Inhibitor Therapy: Results of a
Phase 2 Randomized Study of Two Dose Levels (Abstract
#685)
Session Name: 634. Myeloproliferative Syndromes: Clinical:
Emerging Therapies and Prognostic Scoring in Myelofibrosis and
Other MPNs Session Date: Monday, December 3, 2018 Session Time:
10:30 a.m. PT - 12:00 p.m. PT Presentation Time: 10:30 a.m. PT The
oral presentation will highlight efficacy and safety data from a
primary analysis of IMbark, a Phase 2 clinical trial that evaluated
two starting dose levels of imetelstat (either 4.7 mg/kg or 9.4
mg/kg administered by intravenous infusion every three weeks) in
more than 100 patients with Intermediate-2 or High-risk
myelofibrosis (MF) who have relapsed after or are refractory to
prior treatment with a JAK inhibitor. More mature data from the
extension phase of IMbark, including median overall survival, is
expected to be presented.
Analyst and Investor Event
On December 10, 2018, Geron plans to host a webcasted event for
analysts and investors. At the event, an investigator from each of
the IMbark and Part 1 of IMerge trials will reprise the oral
presentations from the ASH Annual Meeting. A press release with
event details, including how to access a webcast link, will be
available at the end of November.
About Imetelstat
Imetelstat is a novel, first-in-class telomerase inhibitor
exclusively owned by Geron and being developed in hematologic
myeloid malignancies. Early clinical data suggest imetelstat may
have disease-modifying activity through the suppression of
malignant progenitor cell clone proliferation, which allows
potential recovery of normal hematopoiesis. Ongoing clinical
studies of imetelstat include a Phase 2/3 trial called IMerge in
lower risk myelodysplastic syndromes (MDS) and a Phase 2 trial
called IMbark in Intermediate-2 to High-risk myelofibrosis.
Imetelstat received Fast Track designation from the United States
Food and Drug Administration for the treatment of patients with
transfusion-dependent anemia due to lower risk MDS who are
non-del(5q) and refractory or resistant to an erythroid stimulating
agent.
About Geron
Geron is a clinical stage biopharmaceutical company focused on
the development and potential commercialization of a first-in-class
telomerase inhibitor, imetelstat, in hematologic myeloid
malignancies. For more information about Geron, visit
www.geron.com.
Use of Forward-Looking Statements
Except for the historical information contained herein, this
press release contains forward-looking statements made pursuant to
the “safe harbor” provisions of the Private Securities Litigation
Reform Act of 1995. Investors are cautioned that such statements,
include, without limitation, those regarding: (i) the prospects for
imetelstat; (ii) that more mature data for IMbark and IMerge will
be presented at the ASH meeting in December 2018; (iii) that
imetelstat may have disease-modifying activity; and (iv) other
statements that are not historical facts, constitute
forward-looking statements. These statements involve risks and
uncertainties that can cause actual results to differ materially
from those in such forward-looking statements. These risks and
uncertainties, include, without limitation, risks and uncertainties
related to: (i) Janssen’s and the investigators’ ability to collect
additional and more mature data from IMbark and IMerge for an
update at ASH; and (ii) whether imetelstat is able to
demonstrate disease-modifying activity. Additional information on
the above risks and uncertainties and additional risks,
uncertainties and factors that could cause actual results to differ
materially from those in the forward-looking statements are
contained in Geron’s periodic reports filed with the Securities and
Exchange Commission under the heading “Risk Factors,” including
Geron’s quarterly report on Form 10-Q for the quarter ended June
30, 2018. Undue reliance should not be placed on forward-looking
statements, which speak only as of the date they are made, and the
facts and assumptions underlying the forward-looking statements may
change. Except as required by law, Geron disclaims any obligation
to update these forward-looking statements to reflect future
information, events or circumstances.
CONTACT:
Suzanne MessereInvestor and Media
Relationsinvestor@geron.commedia@geron.com
CG Capital877-889-1972
Geron (NASDAQ:GERN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Geron (NASDAQ:GERN)
Historical Stock Chart
From Sep 2023 to Sep 2024